Navigation Links
Stem Cell Transplant May Help Aggressive MS: Study
Date:3/21/2011

By Amanda Gardner
HealthDay Reporter

MONDAY, March 21 (HealthDay News) -- Stem cell transplants may hold some hope for patients with rapidly progressing multiple sclerosis, the authors of a long-term study report.

The controversial treatment, known as hematopoietic stem cell transplantation (HSCT), involves ablating, or removing, the patients' immune and other blood cells, then replacing it with new bone marrow stem cells from the same patient.

The idea is to "reset the thermostat and start fresh," said Dr. Aaron Miller, chief medical officer for the National Multiple Sclerosis Society and a professor of neurology at Mount Sinai School of Medicine in New York City.

But Miller, who was not involved in the study, doubts the procedure will become a viable option for patients with aggressive multiple sclerosis.

"This is a very heroic form of therapy for multiple sclerosis [MS], which is unlikely, in my view, ever to have a major impact on the field," added Miller. "It's a substantially risky therapy -- the mortality rates have been in the 2-3 percent range . . . and it's hugely expensive."

MS is a disease of the nervous system. There is no known cause or cure, and in severe cases patients may be unable to write, speak or walk.

This study, published in the March 22 issue of Neurology, was begun 15 years ago. Back then, "perhaps we didn't have other good alternatives for aggressive disease," he said. "I think we now have better and safer alternatives."

Those alternatives include the biologic therapies Tysabri (natalizumab) and Gilenya (fingolimod), approved in 2006 and 2010, respectively. But Miller emphasized these can only be considered "potentially" more effective than HSCT because the two have never been tested head-to-head.

The trial organizers reported earlier that 80 percent of patients receiving HSCT treatment had stabilized disease after five years. They also noted positive brain changes on an MRI.

Now, after 15 years, the authors report that overall 25 percent of the 35 initial patients are stabilized. The success rate was better -- 44 percent -- for those with active brain lesions, signaling aggressive disease, they found.

Many had a lessening of their disability, and fewer and smaller lesions in the brain.

But two participants, or 6 percent, died of complications from the transplant.

Research on this aggressive therapy is continuing, say the authors, from Aristotle University of Thessaloniki Medical School in Greece.

But more information might be hard to come by because the treatment's high mortality rate makes it difficult to recruit patients.

Still, they said, HSCT might be a "salvage" therapy for hard-to-treat MS.

"It's a possible treatment strategy, but it remains to be seen how much of a treatment option it is," said Dr. Mark Keegan, associate professor of neurology at the Mayo Clinic in Rochester, Minn.

"We do need ways to treat people with aggressive MS," he added.

More information

Visit the National Multiple Sclerosis Society for more on this disease.

SOURCES: Aaron Miller, M.D., chief medical officer, National Multiple Sclerosis Society, and associate professor of neurology and director, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York City; Mark Keegan, M.D., associate professor of neurology, Mayo Clinic, Rochester, Minn.; March 22, 2011 Neurology


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Survival matching should be used to allocate donated kidneys to transplant recipients
2. Transplant Drug May Fight Rare Lung Disorder
3. Alcohol abuse history influences quality of life following liver transplant
4. Transplanting umbilical cord and menstrual blood-derived stem cells offer hope for disorders
5. White Patients Most Likely to Get Kidney Transplants: Study
6. Kidney Transplant Patients Urged to Keep Fit to Survive
7. Study Rates Success of Corneal Transplants in Kids
8. Redesign of US donor-liver network could boost transplants by several hundred per year
9. Researchers work at the frontiers of islet cell transplantation
10. Gene protects lung from damage due to pneumonia, sepsis, trauma, transplants
11. Transplanted human placenta-derived stem cells show therapeutic potential in stroke models
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stem Cell Transplant May Help  Aggressive MS: Study 
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
(Date:6/23/2016)... 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... America . ... ... ... ...
Breaking Medicine Technology: